Codexis, Inc. (CDXS)

Q: What's priced into Codexis, Inc. (CDXS) stock?

The valuation model describes CDXS as cheap versus peers, while also showing a modest peer premium; model confidence is low. The expectations gap is negative, and the priced-in assessment is tagged justified, with no fragility gates triggered.

Q: What does the Codexis, Inc. (CDXS) outlook hinge on?

For the multi-year view, the main test is whether management delivers its revenue guidance and improves operating income and cash flow. A weaker jobs trend could increase recession concerns for cyclical names, while continued strength from major Healthcare companies could support sector momentum. The evidence on these forward factors is limited.

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.28-2.29%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Codexis, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	25.01M
EPS	—	-0.06
FY 2026 · Annual
Revenue	$72M–$76M	73.89M
EPS	—	-0.376
FY 2027 · Annual
Revenue	—	87.69M
EPS	—	-0.277

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Enhance cash flow from operations towards positive	Cash flow from operations is also improving but still negative.	Improving	cash flow remains negative below -$10M next year	Cash from operations: $-9.643M FY2026-Q2; GAAP. Published target: cash flow from operations improves from -$13.15M towards zero. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-9,643,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Cash used in operations improved from negative $13.1 million in 2026-Q1 to negative $9.6 million in 2026-Q2, showing some progress in cash flow management. The trajectory is delivering modest improvement but cash flow remains negative. Delivery assessment Oct 24, 2026
Improve operating income from negative towards breakeven	It is improving operating income from -$18.95M to -$8.04M.	Intact	operating income worsens or stays below -$8M next year	Operating income: $-11.229M FY2026-Q2; GAAP. Published target: operating income improves from -$8.04M towards zero. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-11,229,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b544a25a-5379-445b-aea0-279004ee970b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating loss increased from $8.0 million in 2026-Q1 to $11.2 million in 2026-Q2, indicating limited progress in improving operating income despite management focus. The trajectory shows a worsening operating loss in the recent quarter. Delivery assessment Oct 24, 2026
Achieve 2026 revenue of $72M to $76M	A primary condition in Codexis, Inc.'s published investment case. The stated target is >= $72M and <= $76M.	Intact	annual revenue falls below $72M in FY26	Revenue: $14.915M FY2026-Q2; GAAP. Published target: >= $72M and <= $76M. Target period is not explicitly aligned with this observation. Source published Aug 11, 202614,915,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b544a25a-5379-445b-aea0-279004ee970b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue was $15.2 million in 2026-Q1 and $14.9 million in 2026-Q2, with full-year guidance reiterated at $72 million to $76 million. The trajectory is consistent with management's stated goal, showing stable quarterly revenue but below the midpoint pace, indicating ongoing delivery efforts. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.09B

$0.09B → $0.09B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$88,928,333	2 / 5
2026-07-25	Unavailable	$88,928,333	2 / 5
2026-07-26	Unavailable	$88,928,333	3 / 5
2026-07-27	Unavailable	$88,928,333	3 / 5
2026-07-28	Unavailable	$88,928,333	3 / 5
2026-07-29	Unavailable	$88,928,330	1 / 6
2026-07-30	Unavailable	$88,928,333	3 / 5
2026-07-31	Unavailable	$88,928,333	3 / 5
2026-08-01	Unavailable	$88,928,333	3 / 5
2026-08-02	Unavailable	$88,928,330	1 / 6
2026-08-03	Unavailable	$88,928,333	3 / 5
2026-08-04	Unavailable	$88,928,333	3 / 5
2026-08-05	Unavailable	$88,928,333	3 / 5
2026-08-06	Unavailable	$88,928,333	3 / 5
2026-08-07	Unavailable	$88,928,333	3 / 5
2026-08-08	Unavailable	$88,928,330	1 / 6
2026-08-09	Unavailable	$88,928,333	3 / 5
2026-08-10	Unavailable	$88,928,333	3 / 5
2026-08-11	Unavailable	$88,928,333	3 / 5
2026-08-12	Unavailable	$88,928,333	3 / 5
2026-08-13	Unavailable	$88,928,333	3 / 5
2026-08-14	Unavailable	$88,928,333	3 / 5
2026-08-15	Unavailable	$88,928,333	3 / 5
2026-08-16	Unavailable	$88,928,333	3 / 5
2026-08-17	Unavailable	$88,928,333	3 / 5
2026-08-18	Unavailable	$88,928,333	3 / 5
2026-08-19	Unavailable	$88,928,333	3 / 5
2026-08-20	Unavailable	$88,436,667	3 / 5
2026-08-21	Unavailable	$88,436,667	3 / 5
2026-08-22	Unavailable	$88,436,667	3 / 5
2026-08-23	Unavailable	$88,436,667	3 / 5
2026-08-24	Unavailable	$88,436,667	3 / 5
2026-08-25	Unavailable	$88,436,667	3 / 5
2026-08-26	Unavailable	$88,436,667	3 / 5
2026-08-27	Unavailable	$88,436,667	3 / 5
2026-08-28	Unavailable	$88,436,667	3 / 5
2026-08-29	Unavailable	$88,436,667	3 / 5
2026-08-30	Unavailable	$88,436,667	3 / 5
2026-08-31	Unavailable	$88,436,667	3 / 5
2026-09-01	Unavailable	$88,436,667	3 / 5
2026-09-02	Unavailable	$88,436,667	3 / 5
2026-09-03	Unavailable	$88,436,667	3 / 5
2026-09-04	Unavailable	$88,436,667	3 / 5
2026-09-05	Unavailable	$88,436,667	3 / 5
2026-09-06	Unavailable	$88,436,667	3 / 5
2026-09-07	Unavailable	$88,436,667	3 / 5
2026-09-08	Unavailable	$88,436,667	3 / 5
2026-09-09	Unavailable	$88,436,667	3 / 5
2026-09-10	Unavailable	$88,436,667	3 / 5
2026-09-11	Unavailable	$88,436,667	3 / 5
2026-09-12	Unavailable	$88,436,667	3 / 5
2026-09-13	Unavailable	$88,436,667	3 / 5
2026-09-14	Unavailable	$88,436,667	3 / 5
2026-09-15	Unavailable	$88,436,667	3 / 5
2026-09-16	Unavailable	$88,436,667	3 / 5
2026-09-17	Unavailable	$88,436,667	3 / 5
2026-09-18	Unavailable	$88,436,667	3 / 5
2026-09-19	Unavailable	$88,436,667	3 / 5
2026-09-20	Unavailable	$88,436,667	3 / 5
2026-09-21	Unavailable	$88,436,667	3 / 5
2026-09-22	Unavailable	$88,436,667	3 / 5
2026-09-23	Unavailable	$87,688,571	3 / 5
2026-09-24	Unavailable	$87,688,571	3 / 5
2026-09-25	Unavailable	$87,688,571	3 / 5
2026-09-26	Unavailable	$87,688,571	3 / 5
2026-09-27	Unavailable	$87,688,571	3 / 5
2026-09-28	Unavailable	$87,688,571	3 / 5
2026-09-29	Unavailable	$87,688,571	3 / 5
2026-09-30	Unavailable	$87,688,571	3 / 5
2026-10-01	Unavailable	$87,688,571	3 / 5
2026-10-02	Unavailable	$87,688,571	3 / 5
2026-10-03	Unavailable	$87,688,571	3 / 5
2026-10-04	Unavailable	$87,688,571	3 / 5
2026-10-05	Unavailable	$87,688,571	3 / 5
2026-10-06	Unavailable	$87,688,571	3 / 5
2026-10-07	Unavailable	$87,688,571	3 / 5
2026-10-08	Unavailable	$87,688,571	3 / 5
2026-10-09	Unavailable	$87,688,571	3 / 5
2026-10-10	Unavailable	$87,688,571	3 / 5
2026-10-11	Unavailable	$87,688,571	3 / 5
2026-10-12	Unavailable	$87,688,571	3 / 5
2026-10-13	Unavailable	$87,688,571	3 / 5
2026-10-14	Unavailable	$87,688,571	3 / 5
2026-10-15	Unavailable	$87,688,571	3 / 5
2026-10-16	Unavailable	$87,688,571	3 / 5
2026-10-17	Unavailable	$87,688,571	3 / 5
2026-10-18	Unavailable	$87,688,571	3 / 5
2026-10-19	Unavailable	$87,688,571	3 / 5
2026-10-20	Unavailable	$87,688,571	3 / 5
2026-10-21	Unavailable	$87,688,571	3 / 5
2026-10-22	Unavailable	$87,688,571	3 / 5
2026-10-23	Unavailable	$87,688,571	3 / 5
2026-10-24	Unavailable	$87,688,571	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	2
2026-06-01	5	2
2026-07-01	5	2
2026-08-01	5	2
2026-09-01	6	2
2026-10-01	6	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Enhance cash flow from operations towards positiveCash from operations: $-9.643M
Improve operating income from negative towards breakevenOperating income: $-11.229M
Achieve 2026 revenue of $72M to $76MRevenue: $14.915M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-63.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Codexis, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business with a high-risk, loss-making profile, rather than an established compounder. The long-term thesis remains intact, but confidence is medium and the next results matter.

What's priced into Codexis, Inc.

The valuation model describes CDXS as cheap versus peers, while also showing a modest peer premium; model confidence is low. The expectations gap is negative, and the priced-in assessment is tagged justified, with no fragility gates triggered.

What the fundamentals likely do

Near term, revenue has been stable at $15.2 million in the first quarter and $14.9 million in the second, and management reaffirmed its $72 million to $76 million full-year guidance. The quarterly revenue pace is below the midpoint pace, while the operating loss widened to $11.2 million and cash used in operations remained negative, despite some improvement. The next results carry elevated miss risk, and a guidance cut would be a meaningful setback.

What Codexis, Inc. hinges on